Safety and efficacy of TAS-102 with bevacizumab for the treatment of unresectable metastatic colorectal cancer-a case report

Satoshi Arakawa; Akihiko Horiguchi; Hirokazu Tomishige; Norihiko Kawabe; Hidetoshi Nagata; Shin Ishihara; Masahiro Ito; Yukio Asano; Ryotaro Ito; Masashi Isetani; Kentaro Shimizu; Kenshiro Kamio; Toki Kawai; Hironobu Yasuoka; Yoshihiro Imaeda

Safety and efficacy of TAS-102 with bevacizumab for the treatment of unresectable metastatic colorectal cancer-a case report

Satoshi Arakawa
, Akihiko Horiguchi
, Hirokazu Tomishige
, Norihiko Kawabe
, Hidetoshi Nagata
, Shin Ishihara
, Masahiro Ito
, Yukio Asano
, Ryotaro Ito
, Masashi Isetani
, Kentaro Shimizu
, Kenshiro Kamio
, Toki Kawai
, Hironobu Yasuoka
, Yoshihiro Imaeda

Research output: Contribution to journal › Review article › peer-review

Abstract

Chemotherapy with TAS-102 with bevacizumab (Bmab) is a new treatment for metastatic colorectal cancer. A 67-year-old male patient with synchronous multiple liver metastases was treated with TAS-102 with Bmab as a fifth-line chemotherapy. It was demonstrated that liver metastases decreased in size by 13% by computed tomography (CT) after 3 months of TAS-102 with Bmab therapy. The Grade 3 or worst adverse event that was experienced was neutropenia. The patient was able to continue treatment with TAS-102 with Bmab for 6 months. TAS-102 with Bmab treatment was safety and efficacious as a late-line chemotherapy treatment for metastatic colorectal cancer.

Original language	English
Pages (from-to)	649-651
Number of pages	3
Journal	Japanese Journal of Cancer and Chemotherapy
Volume	45
Issue number	4
Publication status	Published - 04-2018

All Science Journal Classification (ASJC) codes

Oncology
Cancer Research

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Cite this

Arakawa, S., Horiguchi, A., Tomishige, H., Kawabe, N., Nagata, H., Ishihara, S., Ito, M., Asano, Y., Ito, R., Isetani, M., Shimizu, K., Kamio, K., Kawai, T., Yasuoka, H., & Imaeda, Y. (2018). Safety and efficacy of TAS-102 with bevacizumab for the treatment of unresectable metastatic colorectal cancer-a case report. Japanese Journal of Cancer and Chemotherapy, 45(4), 649-651.

@article{293d115fe10f4e538fd53ddf58b52713,

title = "Safety and efficacy of TAS-102 with bevacizumab for the treatment of unresectable metastatic colorectal cancer-a case report",

abstract = "Chemotherapy with TAS-102 with bevacizumab (Bmab) is a new treatment for metastatic colorectal cancer. A 67-year-old male patient with synchronous multiple liver metastases was treated with TAS-102 with Bmab as a fifth-line chemotherapy. It was demonstrated that liver metastases decreased in size by 13\% by computed tomography (CT) after 3 months of TAS-102 with Bmab therapy. The Grade 3 or worst adverse event that was experienced was neutropenia. The patient was able to continue treatment with TAS-102 with Bmab for 6 months. TAS-102 with Bmab treatment was safety and efficacious as a late-line chemotherapy treatment for metastatic colorectal cancer.",

author = "Satoshi Arakawa and Akihiko Horiguchi and Hirokazu Tomishige and Norihiko Kawabe and Hidetoshi Nagata and Shin Ishihara and Masahiro Ito and Yukio Asano and Ryotaro Ito and Masashi Isetani and Kentaro Shimizu and Kenshiro Kamio and Toki Kawai and Hironobu Yasuoka and Yoshihiro Imaeda",

year = "2018",

month = apr,

language = "English",

volume = "45",

pages = "649--651",

journal = "Japanese Journal of Cancer and Chemotherapy",

issn = "0385-0684",

publisher = "Japanese Journal of Cancer and Chemotherapy Publishers Inc.",

number = "4",

}

Arakawa, S, Horiguchi, A, Tomishige, H, Kawabe, N, Nagata, H , Ishihara, S , Ito, M , Asano, Y, Ito, R, Isetani, M, Shimizu, K, Kamio, K, Kawai, T, Yasuoka, H & Imaeda, Y 2018, 'Safety and efficacy of TAS-102 with bevacizumab for the treatment of unresectable metastatic colorectal cancer-a case report', Japanese Journal of Cancer and Chemotherapy, vol. 45, no. 4, pp. 649-651.

TY - JOUR

T1 - Safety and efficacy of TAS-102 with bevacizumab for the treatment of unresectable metastatic colorectal cancer-a case report

AU - Arakawa, Satoshi

AU - Horiguchi, Akihiko

AU - Tomishige, Hirokazu

AU - Kawabe, Norihiko

AU - Nagata, Hidetoshi

AU - Ishihara, Shin

AU - Ito, Masahiro

AU - Asano, Yukio

AU - Ito, Ryotaro

AU - Isetani, Masashi

AU - Shimizu, Kentaro

AU - Kamio, Kenshiro

AU - Kawai, Toki

AU - Yasuoka, Hironobu

AU - Imaeda, Yoshihiro

PY - 2018/4

Y1 - 2018/4

N2 - Chemotherapy with TAS-102 with bevacizumab (Bmab) is a new treatment for metastatic colorectal cancer. A 67-year-old male patient with synchronous multiple liver metastases was treated with TAS-102 with Bmab as a fifth-line chemotherapy. It was demonstrated that liver metastases decreased in size by 13% by computed tomography (CT) after 3 months of TAS-102 with Bmab therapy. The Grade 3 or worst adverse event that was experienced was neutropenia. The patient was able to continue treatment with TAS-102 with Bmab for 6 months. TAS-102 with Bmab treatment was safety and efficacious as a late-line chemotherapy treatment for metastatic colorectal cancer.

AB - Chemotherapy with TAS-102 with bevacizumab (Bmab) is a new treatment for metastatic colorectal cancer. A 67-year-old male patient with synchronous multiple liver metastases was treated with TAS-102 with Bmab as a fifth-line chemotherapy. It was demonstrated that liver metastases decreased in size by 13% by computed tomography (CT) after 3 months of TAS-102 with Bmab therapy. The Grade 3 or worst adverse event that was experienced was neutropenia. The patient was able to continue treatment with TAS-102 with Bmab for 6 months. TAS-102 with Bmab treatment was safety and efficacious as a late-line chemotherapy treatment for metastatic colorectal cancer.

UR - https://www.scopus.com/pages/publications/85049413593

UR - https://www.scopus.com/pages/publications/85049413593#tab=citedBy

M3 - Review article

C2 - 29650823

AN - SCOPUS:85049413593

SN - 0385-0684

VL - 45

SP - 649

EP - 651

JO - Japanese Journal of Cancer and Chemotherapy

JF - Japanese Journal of Cancer and Chemotherapy

IS - 4

ER -

Safety and efficacy of TAS-102 with bevacizumab for the treatment of unresectable metastatic colorectal cancer-a case report

Abstract

All Science Journal Classification (ASJC) codes

UN SDGs

Other files and links

Fingerprint

Cite this